Hydrogel microneedle and effervescent drug reservoir transdermal drug delivery system
By combining hydrogel microneedles with effervescent drug reservoirs, the problem of limited drug loading and release capacity of microneedles is solved, enabling rapid and efficient transdermal drug delivery and improving drug delivery efficiency and therapeutic effect.
Patent Information
- Application Number
- CN202410967114.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-18
- Publication Date
- 2024-11-12
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing microneedles have limited drug loading and release capabilities, while traditional drug delivery methods suffer from first-pass effect and poor patient compliance.
By combining hydrogel microneedles with effervescent drug reservoirs, the hydrogel microneedles form tiny channels on the skin surface, while the effervescent drug reservoirs enhance drug permeability. This combination enables rapid and efficient drug delivery.
This enables rapid and efficient transdermal drug delivery, improving drug delivery efficiency and therapeutic efficacy.
Smart Images

Figure CN118924671A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of medical preparations, in particular to a hydrogel microneedle plus effervescent drug reservoir transdermal drug delivery system. Background Art
[0002] Microneedles are usually arrays of microscopic needle-like structures with a height of 10-1000 µm and a tip diameter of several microns. They can pierce the stratum corneum of the skin and form microporous channels on the epidermis, thereby increasing the transdermal delivery of drugs. Traditional drug delivery methods often require oral administration or injection, which has problems such as first-pass effect and poor patient compliance. Microneedles can directly deliver drugs to the target area on the surface of the skin, avoiding the first-pass effect of drugs and enhancing patient compliance. As a new type of transdermal drug delivery method, microneedle technology that breaks through the stratum corneum barrier in a minimally invasive and painless manner is expected to avoid the gastrointestinal side effects and first-pass effect caused by oral drug absorption, and achieve efficient and convenient drug delivery. However, due to the small space of the microneedle body, its drug loading and release capacity is limited.
[0003] The hydrogel microneedles are made of swellable polymer materials. After piercing the skin in the glassy state, they absorb the skin interstitial fluid and transform into a hydrogel state, forming an unblocked hydrogel channel in the skin. The hydrogel microneedles can be used in conjunction with drug reservoirs to break through the limitations of the limited space of the microneedle body and achieve continuous high-dose drug delivery. In addition, the preparation process of the hydrogel microneedles is relatively simple and low-cost, making them suitable for large-scale production and clinical applications.
[0004] Considering that the water environment provided by the microneedle array formed by the swollen hydrogel is limited in water, a drug reservoir that can quickly disintegrate the drug under the action of a small amount of water will provide a guarantee for the drug delivery efficiency of this type of drug delivery system. Effervescent drug reservoir is a new type of drug preparation technology that increases the release rate of the drug by releasing bubbles inside. At the same time, the release of bubbles can increase the contact area between the drug and the microneedle and accelerate the delivery of the drug. Compared with traditional drug carriers, effervescent drug reservoirs have the advantages of fast drug delivery and high compliance, and are suitable for the delivery and application scenarios of various drugs. Combining hydrogel microneedles with effervescent drug reservoirs can give full play to their respective advantages and further improve the drug delivery efficiency and therapeutic effect. Hydrogel microneedles can form tiny channels on the skin surface to promote transdermal absorption of drugs, while effervescent drug reservoirs can increase the delivery rate of drugs. The combination of the two can achieve faster and more efficient drug delivery. Therefore, the research on hydrogel microneedles plus effervescent drug reservoirs has important theoretical and practical significance and has broad therapeutic prospects. Summary of the invention
[0005] In view of the above situation, in order to solve the deficiencies of the prior art, the purpose of the present invention is to provide a hydrogel microneedle plus effervescent drug reservoir transdermal drug delivery system, which can achieve faster and more efficient drug delivery.
[0006] The technical solution provided by the present invention is that the transdermal drug delivery system comprises a hydrogel microneedle for piercing the skin and an effervescent drug reservoir that can be attached to the hydrogel microneedle for use in conjunction with the drug. The preparation method of the transdermal drug delivery system specifically comprises the following steps: 1) Preparation of PDMS microneedle negative template The PDMS precursor (Sylgard184) and the curing agent were stirred and mixed at a mass ratio of 10:1, and injected into a container containing a positive microneedle mold (microneedle length of 850 μm). After the bubbles were eliminated, the mold was placed at 37 °C for 8-30 h to completely cure. After curing, the positive microneedle mold and PDMS were separated to obtain a negative PDMS microneedle template. 2) Preparation of hydrogel microneedles Dissolve the hydrogel microneedle material in ultrapure water, the mass percentage of the hydrogel microneedle material to the ultrapure water is 24-30%:70-76%, centrifuge at 5000 rpm for 5 min to remove bubbles and ensure the uniformity of the hydrogel, and obtain a hydrogel microneedle solution. Add the hydrogel microneedle solution to the PDMS microneedle negative template prepared in step 1), centrifuge at 3500 rpm for 20 min; dry at 20-37°C for 8-30 h, crosslink at 121°C for 24 h, and demold to obtain a hydrogel microneedle; 3) Preparation of hydrogel microneedles and effervescent drug reservoirs The effervescent agent, drug, and hydrogel microneedle material were placed in a 50 mL test tube at a ratio of 0.5-1.5:1:1-2, and placed in an 80 °C oven for 15 min to dissolve PEG6000. The tube was vortexed to ensure uniform dispersion, and then placed in the hydrogel microneedle prepared in step 2), left to solidify at room temperature, and demolded to obtain a hydrogel microneedle plus effervescent drug reservoir.
[0007] The microneedle array is composed of one or more microneedles, each of which has a length of 50-5000 µm and is used to pierce the stratum corneum barrier of the skin and deliver drugs transdermally.
[0008] The effervescent agent is prepared according to the ratio of acid to base = 1:3, wherein the acid is one of citric acid, malic acid, tartaric acid, boric acid and fumaric acid; and the base is one of sodium bicarbonate and sodium carbonate.
[0009] In the step 2), the hydrogel microneedle material includes but is not limited to a mixture of one or more of PEG200, PEG6000, monomer polymers or copolymers of polyvinyl alcohol, PVA, PVP and their derivatives, hyaluronic acid, gelatin, dextrin, cyclodextrin derivatives, dextran, mannitol, acetate, carboxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, ethyl cellulose, microcrystalline cellulose, chondroitin, dextran, sucrose, chitosan, sodium alginate, pullulan, maltose, lactose, pullulan, methacryloyl hyaluronic acid, polyethylene glycol diacrylate (PEGDA), and methyl vinyl ether-maleic anhydride copolymer.
[0010] The application of the hydrogel microneedle plus effervescent drug reservoir in the preparation of transdermal drug delivery.
[0011] The hydrogel microneedles of the present invention can form tiny channels on the skin surface to promote transdermal absorption of drugs, while the effervescent drug reservoir can improve the permeability of drugs. The combination of the two can achieve faster and more efficient drug delivery, greatly improving the efficiency of transdermal delivery, and is an innovation in transdermal drug delivery systems. BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Figure 1 Schematic diagram of the hydrogel microneedle plus drug reservoir prepared in Example 1 of the present invention.
[0013] Figure 2 Schematic diagram of the hydrogel microneedles prepared in Example 1 of the present invention.
[0014] Figure 3 This is a graph showing the swelling rate of the hydrogel microneedles prepared in Example 1 of the present invention in 2 h.
[0015] Figure 4 This is a schematic diagram of the appearance of a hydrogel microneedle plus an effervescent drug reservoir made of different proportions of the effervescent agent: drug: PEG6000 of the present invention.
[0016] Figure 5 The disintegration time of the effervescent drug reservoir prepared in Example 1 of the present invention.
[0017] Figure 6 Schematic diagram of in vitro release curves of the hydrogel microneedle plus effervescent drug reservoir and the hydrogel microneedle plus non-effervescent drug reservoir of the present invention. DETAILED DESCRIPTION
[0018] The specific implementation of the present invention is further described in detail below in conjunction with the accompanying drawings and examples. Example
[0019] The present invention, when implemented, specifically comprises the following steps: 1) Preparation of PDMS microneedle negative template The PDMS precursor (Sylgard184) and the curing agent were stirred and mixed at a mass ratio of 10:1, and injected into a container containing a positive microneedle mold (microneedle length of 850 µm). After the bubbles were eliminated, the mold was placed at 37 °C for 24 h to completely cure. After curing, the positive microneedle mold and PDMS were separated to obtain a negative PDMS microneedle mold. 2) Preparation of hydrogel microneedles Dissolve 1.5 g PVA in the required amount of water, then add 0.15 g CA and 0.75 g PVP to dissolve, stir to fully dissolve (15% w / w PVA, 1.5% w / w CA, 7.5% w / w PVP and 76% DI water, 10 g); centrifuge at 5000 rpm for 5 min to remove bubbles and ensure the uniformity of the hydrogel to obtain a hydrogel microneedle solution, add the hydrogel microneedle solution to the PDMS microneedle negative template prepared in step 1), centrifuge at 3500 rpm for 20 min; dry at 37 ° C for 48 h, cross-link at 121 ° C for 24 h, demold, and obtain a hydrogel microneedle; The hydrogel microneedles prepared in this embodiment are as follows Figure 2 As shown, the appearance is complete and the needle tip is in good shape. Figure 3 It can be seen that the microneedle swelling rate reached a maximum of about 449.27% in 2 hours, and its equilibrium water content was 77.73%.
[0020] 3) The effervescent agent (n sodium bicarbonate: n citric acid = 3:1), drug, and PEG6000 were placed in 50 mL test tubes at a ratio of 1:1:1, 1:1:1.5, 1:1:2, 1.5:1:1, and 0.5:1:2, respectively. The tubes were placed in an 80 °C oven for 15 min to dissolve PEG6000. The tubes were vortexed to ensure uniform dispersion. The tubes were then placed in the hydrogel microneedles prepared in step 2) and allowed to solidify at room temperature. The tubes were demolded to obtain hydrogel microneedles with effervescent drug reservoirs.
[0021] Depend on Figure 4 It can be seen that the reservoirs made with the ratio of 1:1:1.5 and 1:1:2 have a more complete appearance, better shape, and evenly dispersed particles; Figure 5 It can be seen that the disintegration time of 1:1:1.5 and 1:1:1 is faster. Taking all factors into consideration, the most preferred formula is effervescent agent: drug: PEG6000 = 1:1:1.5.
[0022] The hydrogel microneedle of the present invention can form tiny channels on the skin surface to promote transdermal absorption of drugs, while the effervescent drug reservoir can improve the permeability of drugs. The combination of the two can achieve more accurate and efficient drug delivery. Before use, the effervescent drug reservoir can be glued to the back plate of the hydrogel microneedle with 10 µL of pure water. When used specifically, the blank microneedle can also be injected with a drug-containing preparation, or the blank microneedle can be coated with a drug-containing preparation, or the skin can be treated with microneedles and then coated with a drug-containing preparation. The relevant test data are as follows:
[0023] 1. Preparation of effervescent drug reservoir: The effervescent agent (n sodium bicarbonate: n citric acid = 3:1), drug, and PEG6000 are placed in a 50 mL tube at a ratio of 1:1:1.5, respectively, and placed in an 80 ° C oven for 15 min to dissolve PEG6000, vortex to ensure its uniform dispersion, and then placed in the hydrogel microneedle prepared by the present invention, left to solidify at room temperature, and demolded; the total mass of the effervescent drug reservoir is 0.035 g, the mass of methotrexate is 0.01 g, the mass of the effervescent agent is 0.01 g, and the mass of PEG6000 is 0.015 g.
[0024] 2. Preparation of non-effervescent drug reservoir: Sodium citrate, drug, and PEG6000 are placed in a 50 mL tube at a ratio of 1:1:1.5, respectively, and placed in an 80 ° C oven for 15 min to dissolve PEG6000, vortex to ensure its uniform dispersion, and then placed in the hydrogel microneedles prepared by the present invention, left to solidify at room temperature, and demolded; the total mass of the non-effervescent drug reservoir is 0.035 g, the mass of methotrexate is 0.01 g, the mass of sodium citrate is 0.01 g, and the mass of PEG6000 is 0.015 g.
[0025] 3. Add 8 mL of PBS solution (pH 7.4) as the receiving solution to the receiving chamber of the Franz diffusion cell, and stir magnetically at 750 r / min in a 37°C constant temperature water bath. Treat the ex vivo C57 mouse skin and trim it to a shape suitable for the Franz diffusion cell. Then place the microneedle and drug reservoir in the center of the mouse skin, press for 30 s to insert the microneedle into the skin, and place a stainless steel cylinder (diameter 16.6 mm, mass 12.0 g) on the top of each microneedle to keep the microneedle and the skin in full contact. Place the skin with the inserted microneedle between the supply chamber and the receiving chamber, and expel the bubbles so that the receiving medium liquid surface is in full contact with the mouse skin. Take 200 μL of the receiving solution from the receiving chamber at 1, 2, 3, 4, 5, 6, 8, and 24 h, and add 200 μL of PBS solution (pH 7.4) to the receiving chamber. After 24 hours of application, the microneedles were removed and the mouse skin was taken to make skin homogenate. The skin homogenate and the receptor fluid were centrifuged at 3000 r / min for 10 minutes, and the supernatant was measured by high-performance liquid chromatography for the concentration of methotrexate. The experiment was carried out three times in parallel, and the release curve was drawn with the cumulative release amount as the ordinate and the release time as the abscissa.
[0026] 4. The drug reservoir is loaded with about 10 mg of drug. Figure 6 As shown in the figure, the effervescent drug reservoir releases drugs faster than the drug reservoir without effervescent agent. After 24 h, the cumulative drug released by PVP+PVA+CA hydrogel microneedles plus effervescent drug reservoir was 392.58±209.04 μg, accounting for 3.93% of the total drug amount. A part of the drug exists in the skin tissue, and the drug content of the skin sample is 19.99±8.07 μg, accounting for 2.00% of the total drug amount. After 24 h, the cumulative drug released by PVP+PVA+CA hydrogel microneedles plus non-effervescent drug reservoir was 54.41±14.76 μg, accounting for 5.44% of the total drug amount, and the drug content of the skin sample was 28.80±25.12 μg, accounting for 2.88% of the total drug amount.
[0027] After repeated tests and practices, other embodiments have obtained the same or similar test results as the above examples, which will not be described in detail one by one.
[0028] The hydrogel microneedles of the present invention can form tiny channels on the skin surface to promote transdermal absorption of drugs, while the effervescent drug reservoir can increase the drug delivery speed. The combination of the two can achieve more accurate and efficient drug delivery, greatly improving the transdermal release efficiency of drugs, and has good promotion and application value.
[0029] It should be pointed out that the above is only a preferred embodiment of the present invention and does not limit the present invention in any form. Any technician familiar with the profession can make changes or modify the technical contents disclosed above into equivalent embodiments with equivalent changes without departing from the scope of the technical solution of the present invention, which all fall within the protection scope of the present invention.
Claims
1. A hydrogel microneedle plus effervescent drug reservoir transdermal drug delivery system, characterized in that: The specific steps include: 1) Preparation of PDMS microneedle negative template The PDMS precursor Sylgard184 and the curing agent were stirred and mixed at a mass ratio of 10:1, and injected into the container containing the microneedle positive mold. After the bubbles were eliminated, the mixture was placed at 37°C for 24 hours to completely cure. After curing, the microneedle positive mold and PDMS were separated to obtain a PDMS microneedle negative template. 2) Preparation of hydrogel microneedles Dissolve the hydrogel microneedle material in ultrapure water, the mass percentage of the hydrogel microneedle material to the ultrapure water is 24-30%:70-76%, centrifuge at 5000rpm for 5min to remove bubbles and ensure the uniformity of the hydrogel, and obtain a hydrogel microneedle solution. Add the hydrogel microneedle solution to the PDMS microneedle negative template prepared in step 1), centrifuge at 3500rpm for 20min; dry at 37°C for 48h, crosslink at 121°C for 24h, and demold to obtain a hydrogel microneedle; 3) Preparation of hydrogel microneedles and effervescent drug reservoirs The effervescent agent, drug, and hydrogel microneedle material were placed in a 50 mL test tube at a ratio of 1-2:1:0.5-1.5, and placed in an 80°C oven for 15 min to dissolve PEG6000. The tube was vortexed to ensure uniform dispersion, and then placed in the hydrogel microneedle prepared in step 2), left to solidify at room temperature, and demolded to obtain a hydrogel microneedle plus effervescent drug reservoir.
2. The hydrogel microneedle plus effervescent drug reservoir transdermal drug delivery system according to claim 1, characterized in that: The microneedle array is composed of one or more microneedles, each of which has a length of 50-5000µm and is used to pierce the stratum corneum barrier of the skin and deliver drugs transdermally.
3. The hydrogel microneedle plus effervescent drug reservoir transdermal drug delivery system according to claim 1, characterized in that: The effervescent agent is prepared according to the ratio of acid to base = 1:3, wherein the acid is one of citric acid, malic acid, tartaric acid, boric acid and fumaric acid; and the base is one of sodium bicarbonate and sodium carbonate.
4. The hydrogel microneedle plus effervescent drug reservoir transdermal drug delivery system according to claim 1, characterized in that: In the step 2), the hydrogel microneedle material is a mixture of one or more of PEG200, PEG6000, monomer polymers or copolymers of polyvinyl alcohol, PVA, PVP and their derivatives, hyaluronic acid, gelatin, dextrin, cyclodextrin derivatives, dextran, mannitol, acetate, carboxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, ethyl cellulose, microcrystalline cellulose, chondroitin, dextran, sucrose, chitosan, sodium alginate, pullulan, maltose, lactose, pullulan, methacryloyl hyaluronic acid, polyethylene glycol diacrylate, and methyl vinyl ether-maleic anhydride copolymer.
5. Use of the hydrogel microneedle plus effervescent drug reservoir according to any one of claims 1 to 4 in the preparation of transdermal drug delivery.
Citation Information
Patent Citations
Hydrogel microneedle with replaceable drug-loading reservoir and preparation method of hydrogel microneedle
CN115154883A
Effervescent microneedle capable of releasing medicine to deep layer of skin as well as preparation method and application of effervescent microneedle
CN116531312A
Hydrogel microneedle and preparation method thereof
CN117815163A
Cosmetic or dermopharmaceutical patch containing, in an anhydrous polymeric matrix, at least one active compound which is, in particular, unstable in oxidizing mediums, and at least one water-absorbing agent
US6063398A
Apparatus and method for transdermal delivery of a 5-hydroxytrytamine antagonist
WO2008115599A1
